Therefore, inhibition of the KV10.1 could increase the survival of patients with the fibrosarcoma [12], ovary carcinoma [13], glioblastoma [14], acute lymphoid leukaemia [15], gastric [16], head and neck [17] and colon cancers [18], all entities where a correlation between KV10.1 and poorer outcome has been documented. Here, KCNH1 is linked to fibrosarcoma.